Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pamrevlumab in Non-Ambulatory Duchenne Muscular Dystrophy
NCT02606136Phase 2Terminated
- Sponsor
- FibroGen
- Start
- Jan 2016
- Primary completion
- May 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of pamrevlumab in Duchenne muscular dystrophy (DMD), sponsored by FibroGen. Started Jan 2016; status: terminated.
02
Drugs
pamrevlumab
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT02606136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02606136.